JP2008500356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500356A5 JP2008500356A5 JP2007515279A JP2007515279A JP2008500356A5 JP 2008500356 A5 JP2008500356 A5 JP 2008500356A5 JP 2007515279 A JP2007515279 A JP 2007515279A JP 2007515279 A JP2007515279 A JP 2007515279A JP 2008500356 A5 JP2008500356 A5 JP 2008500356A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- topical composition
- independently hydrogen
- receptor agonist
- adrenergic receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- 230000000699 topical effect Effects 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000002674 ointment Substances 0.000 claims 5
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 4
- -1 tetrahydrozaline Chemical compound 0.000 claims 4
- 241001303601 Rosacea Species 0.000 claims 3
- 210000002565 arteriole Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000006071 cream Substances 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 201000004700 rosacea Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 229960003679 brimonidine Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 229960005139 epinephrine Drugs 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000003589 local anesthetic agent Substances 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 229960005192 methoxamine Drugs 0.000 claims 2
- 229960005016 naphazoline Drugs 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 2
- 229960001528 oxymetazoline Drugs 0.000 claims 2
- 235000015927 pasta Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960001802 phenylephrine Drugs 0.000 claims 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229960000833 xylometazoline Drugs 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 claims 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57414204P | 2004-05-25 | 2004-05-25 | |
| US60/574,142 | 2004-05-25 | ||
| US10/853,585 | 2004-05-25 | ||
| US10/853,585 US7439241B2 (en) | 2003-05-27 | 2004-05-25 | Compounds, formulations, and methods for treating or preventing rosacea |
| PCT/US2005/018288 WO2005115395A2 (en) | 2004-05-25 | 2005-05-25 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011263425A Division JP5547705B2 (ja) | 2004-05-25 | 2011-12-01 | 紅斑を治療又は予防するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500356A JP2008500356A (ja) | 2008-01-10 |
| JP2008500356A5 true JP2008500356A5 (enExample) | 2008-03-27 |
| JP4955543B2 JP4955543B2 (ja) | 2012-06-20 |
Family
ID=35451386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515279A Expired - Fee Related JP4955543B2 (ja) | 2004-05-25 | 2005-05-25 | 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法 |
| JP2011263425A Expired - Fee Related JP5547705B2 (ja) | 2004-05-25 | 2011-12-01 | 紅斑を治療又は予防するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011263425A Expired - Fee Related JP5547705B2 (ja) | 2004-05-25 | 2011-12-01 | 紅斑を治療又は予防するための組成物 |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2481412B1 (enExample) |
| JP (2) | JP4955543B2 (enExample) |
| KR (1) | KR101257046B1 (enExample) |
| CN (2) | CN101426502A (enExample) |
| AU (1) | AU2005247467B2 (enExample) |
| BR (1) | BRPI0511519A (enExample) |
| CA (2) | CA2567401C (enExample) |
| DK (1) | DK1761266T3 (enExample) |
| ES (2) | ES2647618T3 (enExample) |
| MX (1) | MXPA06013649A (enExample) |
| NZ (1) | NZ552325A (enExample) |
| PL (1) | PL1761266T3 (enExample) |
| PT (1) | PT1761266E (enExample) |
| SI (1) | SI1761266T1 (enExample) |
| WO (1) | WO2005115395A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| GB0611241D0 (en) * | 2006-06-07 | 2006-07-19 | Daniolabs Ltd | The treatment of increased sebum production |
| EP2493309A4 (en) * | 2009-10-26 | 2013-05-01 | Galderma Pharma Sa | METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA |
| EP2329849B1 (en) * | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| MX2012010824A (es) | 2010-03-26 | 2012-10-10 | Galderma Res & Dev | Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema. |
| RU2535008C2 (ru) | 2010-03-26 | 2014-12-10 | Галдерма Ресерч Энд Девелопмент | Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии |
| US8492422B2 (en) | 2010-09-16 | 2013-07-23 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions |
| US20120082625A1 (en) * | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| CA2814975A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel composition |
| SG189896A1 (en) * | 2010-10-21 | 2013-06-28 | Galderma Sa | Brimonidine gel compositions and methods of use |
| CN101972272B (zh) * | 2010-10-31 | 2012-07-04 | 无锡龙腾画材有限公司 | 一种二氧化氯皮肤凝胶及其制备方法 |
| JP2013542991A (ja) * | 2010-11-16 | 2013-11-28 | アラーガン インコーポレイテッド | （３−（１−（１ｈ−イミダゾール−４−イル）エチル）−２−メチルフェニル）メタノールを含む医薬組成物 |
| AU2012217858A1 (en) * | 2011-02-15 | 2013-09-05 | Allergan, Inc. | Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea |
| FR2977493B1 (fr) * | 2011-07-05 | 2014-02-14 | Galderma Res & Dev | Nouvelle composition anesthesique stable pour la reduction des reactions cutanees |
| BR112014009210A2 (pt) * | 2011-10-19 | 2017-04-18 | Galderma Sa | método para a redução da vermelhidão facial cutânea |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| AU2012340806B2 (en) | 2011-11-21 | 2017-10-19 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
| AU2014262960A1 (en) * | 2013-05-06 | 2015-11-26 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| AU2014292879A1 (en) * | 2013-07-26 | 2016-02-11 | Galderma Research & Development | Compositions for treating skin thickening |
| CN105764496B (zh) | 2013-10-07 | 2020-09-25 | 帝国制药美国公司 | 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物 |
| TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| TWI709417B (zh) | 2013-10-07 | 2020-11-11 | 美商帝國製藥美國股份有限公司 | 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物 |
| JP6659819B2 (ja) * | 2015-07-09 | 2020-03-04 | ガルデルマ・ソシエテ・アノニム | 化学療法に関連する脱毛の軽減方法 |
| JP2017052723A (ja) * | 2015-09-10 | 2017-03-16 | 株式会社Ｌｔｔバイオファーマ | ドライアイ改善剤 |
| CN106727462B (zh) * | 2016-11-14 | 2019-04-09 | 四川省人民医院 | 一种治疗面部皮炎的药物及其应用 |
| SG11202106716RA (en) * | 2019-01-12 | 2021-07-29 | Cellix Bio Private Ltd | Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof |
| US20220218590A1 (en) * | 2019-05-14 | 2022-07-14 | Abend Fritz Ventures Llc | Compositions and methods for removal of skin adhesive patches, products, and residual adhesives |
| JP2023539595A (ja) * | 2020-08-26 | 2023-09-15 | オティカラ，インコーポレーテッド | 鼻、耳及び他の組織の感染症及び／又は炎症を処置するための組成物、デバイス及び方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3278447A (en) | 1963-12-02 | 1966-10-11 | Cloro Bac Products Inc | Process for stabilizing chlorine dioxide solution |
| US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US4164570A (en) * | 1973-09-24 | 1979-08-14 | David Clough | Stabilized aqueous catecholamine solutions |
| US4285967A (en) * | 1978-06-30 | 1981-08-25 | Estee Lauder Inc. | Cosmetic preparation for reducing redness of blemishes |
| US4256763A (en) * | 1978-09-19 | 1981-03-17 | Mchugh John E | Treatment of herpes simplex infections and acne |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4908387A (en) * | 1988-06-06 | 1990-03-13 | The Regents Of The University Of California | Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| IT1252692B (it) * | 1991-11-27 | 1995-06-23 | Zambon Spa | Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi |
| US5736165A (en) | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
| US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
| US5720962A (en) * | 1995-10-04 | 1998-02-24 | Au Pharmaceuticals, Inc. | Analgesic lotion for hemorrhoids and method of making such lotion |
| US6441047B2 (en) * | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| US5910312A (en) * | 1996-10-09 | 1999-06-08 | Ideal Ideas, Inc. | Acne treatment composition with vasoconstrictor |
| US5916574A (en) | 1996-10-09 | 1999-06-29 | Ideal Ideas, Inc. | Method of treating natural poison skin conditions |
| JPH1129482A (ja) * | 1997-05-14 | 1999-02-02 | Taisho Pharmaceut Co Ltd | 医薬組成物 |
| PL340711A1 (en) * | 1997-11-24 | 2001-02-26 | Procter & Gamble | Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability |
| US6159944A (en) * | 1998-02-27 | 2000-12-12 | Synchroneuron, Llc | Method for treating painful conditions of the anal region and compositions therefor |
| IN185228B (enExample) | 1999-02-03 | 2000-12-09 | Bakulesh Mafatlal Dr Khamar | |
| US20020197300A1 (en) * | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
| US6284765B1 (en) * | 2000-04-27 | 2001-09-04 | The University Of North Texas Health Science Center At Fort Worth | (+) naloxone and epinephrine combination therapy |
| US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
| CA2402405C (en) * | 2000-07-14 | 2008-02-12 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| JP3520076B2 (ja) * | 2001-10-02 | 2004-04-19 | 憲司 中村 | 皮膚外用剤 |
| US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
-
2005
- 2005-05-25 CA CA2567401A patent/CA2567401C/en not_active Expired - Fee Related
- 2005-05-25 CN CNA2005800223827A patent/CN101426502A/zh active Pending
- 2005-05-25 PL PL05754754T patent/PL1761266T3/pl unknown
- 2005-05-25 DK DK05754754.9T patent/DK1761266T3/da active
- 2005-05-25 PT PT57547549T patent/PT1761266E/pt unknown
- 2005-05-25 WO PCT/US2005/018288 patent/WO2005115395A2/en not_active Ceased
- 2005-05-25 ES ES12165557.5T patent/ES2647618T3/es not_active Expired - Lifetime
- 2005-05-25 JP JP2007515279A patent/JP4955543B2/ja not_active Expired - Fee Related
- 2005-05-25 CN CN201410590016.2A patent/CN104490884A/zh active Pending
- 2005-05-25 KR KR1020067027124A patent/KR101257046B1/ko not_active Expired - Fee Related
- 2005-05-25 EP EP12165557.5A patent/EP2481412B1/en not_active Expired - Lifetime
- 2005-05-25 ES ES05754754T patent/ES2424644T3/es not_active Expired - Lifetime
- 2005-05-25 EP EP05754754.9A patent/EP1761266B1/en not_active Expired - Lifetime
- 2005-05-25 NZ NZ552325A patent/NZ552325A/en not_active IP Right Cessation
- 2005-05-25 SI SI200531745T patent/SI1761266T1/sl unknown
- 2005-05-25 BR BRPI0511519-1A patent/BRPI0511519A/pt not_active Application Discontinuation
- 2005-05-25 CA CA2824612A patent/CA2824612C/en not_active Expired - Fee Related
- 2005-05-25 MX MXPA06013649A patent/MXPA06013649A/es not_active Application Discontinuation
- 2005-05-25 AU AU2005247467A patent/AU2005247467B2/en not_active Ceased
-
2011
- 2011-12-01 JP JP2011263425A patent/JP5547705B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500356A5 (enExample) | ||
| CA2530938A1 (en) | Compounds, formulations, and methods for treating or preventing rosacea | |
| RU2538729C2 (ru) | Применение агонистов альфа 2 адренергических рецепторов для лечения или предотвращения псориаза | |
| CA2567401C (en) | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | |
| AU2010313643B2 (en) | Methods of treating or preventing acute erythema | |
| JP2013511534A5 (enExample) | ||
| RU2012124904A (ru) | КОМБИНАЦИЯ АГОНИСТА α2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И НЕСТЕРОИДНОГО ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ВОСПАЛИТЕЛЬНОГО ПОРАЖЕНИЯ КОЖИ | |
| BR112013009578B1 (pt) | composição tópica em gel e uso de uma composição tópica em gel | |
| JP2013540142A (ja) | 局所ゲル組成物 | |
| CN106535936A (zh) | 治疗手足综合征及与其相关的症状的方法 | |
| US11278548B2 (en) | Methods and compositions for reducing side effects in chemotherapeutic treatments | |
| WO2015054359A1 (en) | Methods and compositions for symptomatic reflief of the common cold | |
| HK1174537A (en) | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |